KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells
| Autor: | Kaoru Niimi, Jun Sakata, Fumitaka Kikkawa, Hiroaki Kajiyama, Ryuichiro Sekiya, Shiro Suzuki, Yosuke Kawai, Takeshi Senga, Kiyosumi Shibata, Fumi Utsumi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research Cell Kinesins Apoptosis Ovary clear-cell carcinoma Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Biomarkers Tumor medicine Carcinoma Humans KIF20A Aged Ovarian Neoplasms epithelial ovarian carcinoma Oncogene business.industry Articles General Medicine Middle Aged Cell cycle Prognosis medicine.disease Molecular medicine Gene Expression Regulation Neoplastic prognostic indicator cell proliferation 030104 developmental biology medicine.anatomical_structure Oncology immunohistochemical staining 030220 oncology & carcinogenesis Clear cell carcinoma Cancer research Adenocarcinoma Female cell cycle Neoplasm Recurrence Local business Adenocarcinoma Clear Cell |
| Zdroj: | Oncology Reports |
| ISSN: | 1791-2431 1021-335X |
| DOI: | 10.3892/or.2018.6401 |
| Popis: | Kinesin family member 20A (KIF20A), which is involved in cytokinesis and intracellular transportation, has been recently reported to be upregulated in several malignancies and may contribute to chemotherapeutic resistance. We examined the distribution and expression of KIF20A in clear-cell carcinoma (CCC) of the ovary to elucidate its clinical significance and molecular mechanism. Paraffin sections from ovarian CCC tissues (N=43) were immunostained with KIF20A antibody, and the staining intensities were semi-quantitatively evaluated. Furthermore, we investigated whether silencing of KIF20A contributes to the proliferation-inhibitory potential using CCC cells. During the observational period, 18 patients (41.9%) developed recurrence. The median time to recurrence was 11.5 months. Patients in the high KIF20A expression group showed poorer progression-free survival (PFS) and overall survival (OS) than those in the low expression group (P=0.0443 and P=0.0478, respectively). In multivariable analyses, KIF20A expression was also a significantly independent indicator of PFS and a marginally significant indicator of OS [PFS: HR (high vs. low), 5.488; 95% CI, 1.410–24.772 (P=0.0136); OS: HR, 2.835; 95% CI, 0.854–11.035, (P=0.0897)]. In in vitro studies, the ovarian CCC cell proliferation was significantly decreased by KIF20A silencing or in the presence of KIF20A inhibitor in CCC cells. Cell cycle G2/M arrest and a higher apoptosis-induced fraction were more frequently observed in si-KIF20A-transfected CCC cells than in the control cells. Although the present study was preliminary, these data indicate the possible involvement of KIF20A in the proliferation of CCC, suggesting that targeting this molecule may contribute to reversing the malignant potential consequently affecting the oncologic outcome of CCC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|